Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-13 |
2024-03 |
-0.12 |
-0.26 |
-0.14 |
-116.67% |
2024-03-11 |
2023-12 |
-0.21 |
N/A |
N/A |
N/A |
2024-03-11 |
2023-12 |
-0.21 |
-0.25 |
-0.04 |
-19.05% |
2023-11-14 |
2023-09 |
-0.17 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.17 |
-0.63 |
-0.46 |
-270.59% |
2023-08-11 |
2023-06 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-12 |
B. Riley Securities |
Upgrade |
|
Buy |
2023-10-08 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-16 |
CHUN JAY |
Director |
102.51K |
Purchase |
2024-05-16 |
JI HENRY H |
Officer and Director |
0.00 |
Purchase |
2024-05-16 |
MA STEPHEN HOI |
Chief Financial Officer |
14.14K |
Purchase |
2024-05-16 |
SHAH JAISIM |
Chief Executive Officer |
0.00 |
Purchase |
2023-09-20 |
SORRENTO THERAPEUTICS, INC. |
Beneficial Owner of more than 10% of a Class of Security |
1.92M |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
State Street Corporation |
7.33M |
40.80M |
4.77% |
2023-06-29 |
Blackrock Inc. |
5.46M |
30.40M |
3.56% |
2023-06-29 |
Vanguard Group Inc |
2.69M |
14.97M |
1.75% |
2023-06-29 |
Shaw D.E. & Co., Inc. |
627.04K |
3.49M |
0.41% |
2023-06-29 |
Rafferty Asset Management, LLC |
620.13K |
3.45M |
0.40% |
2023-06-29 |
Northern Trust Corporation |
585.81K |
3.26M |
0.38% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
5.94M |
17.04M |
3.87% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.56M |
14.26M |
1.67% |
2023-08-30 |
iShares Russell 2000 ETF |
1.43M |
4.11M |
0.93% |
2023-09-29 |
Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh |
620.13K |
868.18K |
0.40% |
2023-08-30 |
iShares Russell 2000 Value ETF |
576.36K |
1.65M |
0.38% |
2023-05-30 |
BlackRock Advantage Small Cap Core Fund |
430.18K |
2.56M |
0.28% |